Livedoid vasculitis - Livedoidne Vaskuliit
Livedoidne Vaskuliit (Livedoid vasculitis) on krooniline nahahaigus, mida esineb peamiselt noortel kuni keskealistel naistel. Üks selle tunnuste kirjeldamiseks kasutatav akronüüm on "Alumiste jäsemete retikulaarse mustriga valulikud purpursed haavandid" (PURPLE). Seda seostatakse mitmete haigustega, sealhulgas kroonilise venoosse hüpertensiooni ja veenilaiendite tekkega.
☆ Saksamaa 2022. aasta Stiftung Warentesti tulemustes oli tarbijate rahulolu ModelDermiga vaid veidi madalam kui tasuliste telemeditsiini konsultatsioonidega.
Sellega võib kaasneda valu.
References
Livedoid vasculopathy on haruldane nahahaigus, mida iseloomustavad valulikud haavandid, mis tekivad säärtele pidevalt tagasi.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy on haruldane nahahaigus, mis põhjustab säärtel korduvaid haavandeid, jättes maha kahvatud armid, mida tuntakse atroofia blanche nime all. Kuigi täpne põhjus on endiselt ebaselge, arvatakse, et peamine tegur on suurenenud vere hüübimine (hypercoagulability) , kusjuures põletik mängib teisejärgulist rolli. Hüübimist soodustavad tegurid on järgmised - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Biopsiates näitab seisund verehüübeid veresoonte sees, veresoonte seinte paksenemist ja armistumist. Ravi hõlmab mitmekülgset lähenemisviisi, mis keskendub verehüüvete ennetamisele selliste ravimitega nagu trombotsüütide vastased ravimid, verevedeldajad ja fibrinolüütiline ravi. Selle nahahaiguse korral võib kasutada erinevaid ravimeid - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy on haruldane seisund, kus kahjustused tekivad mõlemal jalal. Arvatakse, et verehüüvete moodustumine väikestes veresoontes on põhjustatud suurenenud hüübimisest ja trombide lagunemise vähenemisest koos veresoone limaskesta kahjustusega. See esineb sagedamini naistel, eriti vanuses 15–50 aastat. Suitsetamisest loobumine, haavade eest hoolitsemine ja selliste ravimite nagu verevedeldajad ja trombotsüütide agregatsiooni vastased ravimid on olnud tõhusad.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
